Malarsjukhuset Eskilstuna
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at Malarsjukhuset Eskilstuna focuses on patients with atrial fibrillation and advanced chronic kidney disease stage 5. The primary aim is to evaluate the effectiveness and safety of apixaban for stroke prevention, seeking to lower the risk of ischemic events while maintaining an acceptable bleeding profile.
- Efficacy of anticoagulation in CKD stage 5
- Safety of anticoagulants in patients on dialysis
- Impact on incidence of ischemic stroke and systemic embolism
With 10 investigators and two active studies, the department advances cardiovascular care through rigorous evaluation of novel anticoagulant strategies.
Neoplasms
In the oncology unit, the focus is on resectable colon cancer characterized by dMMR/MSI‑H. The trial investigates peri‑operative use of dostarlimab compared with standard treatment, aiming to improve surgical outcomes and long‑term disease control.
- Peri‑operative immunotherapy for resectable colon cancer
- Outcomes in dMMR/MSI‑H tumor subtypes
- Comparison with standard of care approaches
Conducted by a team of 10 investigators, this research contributes to advancing cancer therapeutics at Malarsjukhuset Eskilstuna.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 8 therapeutic areas and 15 of 58 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1Karolinska Institutet2active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Karolinska Institutet2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Malarsjukhuset Eskilstuna
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE | Karolinska University Hospital | Phase II | Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 58 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ciprofloxacin | 2 | Unknown | 2023-04-17 | 2025-11-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.